EG626215 Inhibitors
Ccdc196, a protein characterized by coiled-coil domains, plays a pivotal role in cellular processes, yet the specifics of its functions remain to be fully elucidated. The coiled-coil domains suggest a structural role, potentially involved in protein-protein interactions or cellular organization. Beyond structural considerations, Ccdc196's functional significance may extend to regulatory roles within intricate signaling networks. While the exact biological pathways and cellular processes governed by Ccdc196 remain elusive, its involvement in coiled-coil interactions suggests potential roles in signal transduction, cellular transport, or cytoskeletal organization. Understanding its precise functions is critical to unraveling the complexity of cellular processes influenced by this enigmatic protein.
The inhibition of Ccdc196 involves targeting specific signaling pathways and cellular mechanisms that indirectly modulate its activity. The identified compounds, outlined in the tabulated form, exert their influence through diverse mechanisms. For instance, inhibitors disrupting the RAF/MEK/ERK and PI3K-Akt signaling pathways may impact Ccdc196 by interfering with cascades that regulate its function. Additionally, bromodomain inhibitors and proteasome inhibitors represent alternative avenues for indirect inhibition, potentially altering gene expression and protein turnover associated with Ccdc196. The multifaceted nature of the inhibitors underscores the intricate regulatory network governing Ccdc196, emphasizing the need for further research to decipher its precise functions and the interplay with cellular processes. In summary, Ccdc196 stands as a molecular puzzle, and its inhibition requires a nuanced understanding of the intricate cellular pathways it influences.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor affecting RAF/MEK/ERK signaling. Sorafenib inhibits multiple kinases in the RAF/MEK/ERK pathway, indirectly influencing Ccdc196 by disrupting this signaling cascade, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor affecting PI3K-Akt signaling. LY294002 inhibits PI3K, indirectly influencing Ccdc196 by disrupting the PI3K-Akt pathway, potentially altering cellular processes associated with Ccdc196 function. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
Bromodomain inhibitor affecting BET proteins. JQ1 inhibits BET proteins, indirectly impacting Ccdc196 by modulating gene expression through the inhibition of bromodomain-containing factors, potentially altering cellular processes related to Ccdc196 function. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AKT inhibitor affecting PI3K-Akt signaling. AZD5363 inhibits AKT, indirectly influencing Ccdc196 by disrupting the PI3K-Akt pathway, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor affecting the MAPK pathway. Trametinib inhibits MEK, indirectly influencing Ccdc196 by disrupting the MAPK signaling pathway, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor affecting protein degradation. Bortezomib inhibits the proteasome, indirectly influencing Ccdc196 by altering protein turnover, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
Bromodomain inhibitor affecting BET proteins. I-BET151 inhibits BET proteins, indirectly impacting Ccdc196 by modulating gene expression through the inhibition of bromodomain-containing factors, potentially altering cellular processes related to Ccdc196 function. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
AKT inhibitor affecting PI3K-Akt signaling. MK-2206 inhibits AKT, indirectly influencing Ccdc196 by disrupting the PI3K-Akt pathway, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor affecting the MAPK pathway. Selumetinib inhibits MEK, indirectly influencing Ccdc196 by disrupting the MAPK signaling pathway, potentially modulating cellular processes associated with Ccdc196 function. | ||||||
TG101209 | 936091-14-4 | sc-364731 sc-364731A | 5 mg 50 mg | $255.00 $1455.00 | ||
JAK2 inhibitor affecting JAK-STAT signaling. TG-101348 inhibits JAK2, indirectly influencing Ccdc196 by modulating the JAK-STAT pathway, potentially altering cellular processes associated with Ccdc196 function. | ||||||